このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

SKCD in Early Relapsed/Refractory Multiple Myeloma

2026年11月6日 更新者:wen gao、Beijing Chao Yang Hospital

A Prospective, Multicenter, Open-Label, Single-Arm Phase II Clinical Study Evaluating the Efficacy and Safety of Sonrotoclax, Carfilzomib, Aponermin, and Dexamethasone in Patients With Early Relapsed or Refractory Multiple Myeloma

Multiple myeloma (MM) is a malignant hematologic neoplasm arising from abnormal plasma cells within the bone marrow. Although substantial therapeutic progress has been achieved over the past twenty years, MM remains an incurable disease for the vast majority of patients. When the disease relapses or becomes refractory after 1 to 3 prior lines of therapy (termed early relapsed or refractory multiple myeloma [RRMM]), achieving deep and durable remission during early salvage therapy is critical to extending long-term survival.

Current guideline-recommended second-line therapies exhibit distinct clinical challenges: standard triplet regimens lack head-to-head comparisons, novel cellular therapies (such as CAR-T) are costly and difficult to access, and optimal combinations for early relapse remain undefined. Furthermore, novel targeted therapeutics have predominantly originated overseas, highlighting an urgent need for effective regimens based on innovative domestic agents.

Therapeutic Rationale of the SKCD Regimen: This study evaluates a novel quadruplet combination regimen termed SKCD, comprising four complementary therapeutics:

  • 1. Sonrotoclax: Sonrotoclax (BGB-11417): A highly potent and selective oral BCL-2 inhibitor that restores the cell's internal (mitochondrial) apoptosis pathway.
  • 2. Carfilzomib: Carfilzomib: A second-generation selective proteasome inhibitor that inhibits myeloma cell proliferation and downregulates anti-apoptotic proteins like MCL-1.
  • 3. Aponermin (CPT): Aponermin (CPT): A first-in-class recombinant circularly permuted human TRAIL and DR4/DR5 agonist, independently developed in China and approved for RRMM, which selectively activates external (death receptor) apoptosis.
  • 4. Dexamethasone: Dexamethasone: A synthetic corticosteroid with established anti-myeloma activity that synergizes with BCL-2 and proteasome inhibitors.

Preclinical studies demonstrate that simultaneously stimulating internal mitochondrial apoptosis and external death receptor apoptosis produces synergistic anti-myeloma cytotoxicity. The primary objective of this Phase II study is to evaluate the clinical efficacy (assessed by the best complete response or better rate [>= CR]) and the safety profile of the SKCD quadruplet regimen followed by carfilzomib and dexamethasone (Kd) maintenance therapy in early relapsed RRMM.

調査の概要

状態

募集

介入・治療

詳細な説明

Sonrotoclax is being investigated in combination with carfilzomib, aponermin, and dexamethasone for the treatment of early-line relapsed or refractory multiple myeloma. This use is outside the approved indications in China and is investigational.

研究の種類

介入

入学 (推定)

66

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Beijing Municipality
      • Beijing、Beijing Municipality、中国、100020
        • 募集
        • Beijing Chao-Yang Hospital,Capital Medical University
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria

Candidates must satisfy all of the following inclusion criteria to be enrolled in the study:

  • 1. Age: Age > 18 years, male or female.

  • 2. Measurable Disease: Diagnosed with multiple myeloma according to the 2014 IMWG diagnostic criteria, with measurable disease at screening defined by at least one of the following:

    1. Serum M-protein level > 10 g/L (1.0 g/dL); OR
    2. 24-hour urine M-protein excretion > 200 mg/24 hours; OR
    3. In light chain multiple myeloma without measurable serum or urine M-protein: serum involved free light chain (FLC) > 100 mg/L (10 mg/dL) with an abnormal serum FLC kappa/lambda ratio (normal reference range: 0.26-1.65).
  • 3. Disease Status & Life Expectancy: Patients with early relapsed or refractory multiple myeloma, with an anticipated life expectancy of >= 6 months.

  • 4. Prior Therapy Lines: Must have received 1 to 3 prior systemic treatment lines. Induction therapy followed by autologous stem cell transplantation (ASCT) with or without maintenance therapy is counted as a single line of therapy. Participants must have received at least one regimen containing a proteasome inhibitor (e.g., bortezomib, ixazomib, carfilzomib) and/or an immunomodulatory drug (e.g., lenalidomide, pomalidomide; excluding thalidomide monotherapy), and demonstrated disease progression or relapse during or after such therapy (single-agent or combination). Prior anti-CD38 monoclonal antibody exposure is permitted but not mandatory. Radiotherapy, bisphosphonate therapy, or a single brief course of corticosteroids (equivalent dose not exceeding dexamethasone 20 mg/day for <= 4 days) are not counted as prior systemic treatment lines.

  • 5. Documented Disease Progression: Documented evidence of progressive disease (PD) during or following the most recent anti-myeloma regimen based on IMWG consensus criteria. Progressive disease requires at least one of the following compared with the nadir value:

  • An increase of >= 25% in serum M-protein (with an absolute increase of >= 5 g/L); or an absolute increase of >= 10 g/L if baseline serum M-protein was >= 50 g/L;

  • An increase of >= 25% in 24-hour urine M-protein (with an absolute increase of >= 200 mg/24 h);

  • In patients without measurable serum and urine M-protein, an increase of >= 25% in the difference between involved and uninvolved FLC levels (dFLC, with an absolute increase > 100 mg/L);

  • In patients without measurable serum/urine M-protein and involved FLC, an increase of >= 25% in bone marrow plasma cell percentage (with an absolute increase of >= 10%);

  • Development of new extramedullary plasmacytomas: an increase of >= 50% in the sum of the products of the perpendicular diameters (SPD) of > 1 existing measurable lesion compared to nadir, or an increase of >= 50% in the longest diameter of a pre-existing lesion >= 1 cm;

  • When circulating plasma cells represent the only measurable parameter, an increase of > 50% in circulating plasma cells (with an absolute count of at least 200 cells/uL).

  • 6. Performance Status: Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2 at screening and prior to initiation of study treatment.

  • 7. Organ and Laboratory Function: Adequate hematologic, hepatic, renal, and metabolic organ function prior to enrollment, satisfying:

  • Hemoglobin >= 80 g/L (without red blood cell transfusions or erythropoietin within 7 days prior to laboratory assessment);

  • Platelet count: > 75 x 10⁹/L in patients with < 50% bone marrow nucleated cells composed of plasma cells; > 50 x 10⁹/L in patients with >= 50% bone marrow plasma cells (without platelet transfusions or thrombopoietin receptor agonists within 7 days prior to assessment);

  • Absolute Neutrophil Count (ANC) > 0.5 x 10⁹/L (growth factor support permitted, but G-CSF or GM-CSF must be discontinued for >= 7 days, and pegylated G-CSF for >= 14 days prior to assessment);

  • Hepatic function: AST and ALT <= 2.5 x ULN; Total bilirubin <= 2.5 x ULN, except in patients with congenital hyperbilirubinemia such as Gilbert syndrome (in which direct bilirubin must be < 1.5 x ULN);

  • Renal function: Estimated glomerular filtration rate (eGFR) > 30 mL/min, calculated using the Modification of Diet in Renal Disease (MDRD) equation or measured by 24-hour urinary creatinine clearance;

  • Serum calcium: Albumin-corrected serum calcium <= 14 mg/dL (< 3.5 mmol/L) or ionized calcium <= 6.5 mg/dL.

  • 8. Disease Subtype Definitions: Relapsed, refractory, or clinical relapse defined as follows:

  • Relapsed Disease: Patients who initially achieved a response to prior therapy and subsequently developed confirmed disease progression per IMWG criteria > 60 days after therapy cessation.

  • Refractory Disease: Patients who experienced disease progression per IMWG criteria during prior therapy or within < 60 days of discontinuing prior therapy, or had an M-protein increase of >= 25%.

  • Clinical Relapse: Defined by >= 1 of the following: (1) Development of new bone lesions or soft-tissue plasmacytomas (excluding osteoporotic fractures); (2) Definite increase in the size of existing plasmacytomas or bone lesions (>= 50% increase in SPD of measurable lesions and absolute increase >= 1 cm); (3) Hypercalcemia (> 2.75 mmol/L); (4) Decrease in hemoglobin concentration >= 20 g/L (unrelated to therapy or non-MM causes); (5) Increase in serum creatinine >= 176.8 umol/L (2 mg/dL) from initiation of MM therapy, attributable to myeloma; (6) Hyperviscosity related to serum M-protein.

  • 9. Informed Consent: Voluntary written informed consent signed by the patient or legally authorized representative.

Exclusion Criteria

Candidates meeting any of the following exclusion criteria shall be excluded from study participation:

  • 1. Hypersensitivity: Known contraindication, life-threatening allergy, severe hypersensitivity, or intolerance to any study drug active ingredients or excipients.
  • 2. Prior Antineoplastic Therapy Washout: Prior therapy washout requirements:
  • Targeted therapy, epigenetic therapy, or investigational drug treatment within 21 days or > 5 elimination half-lives (whichever is shorter) prior to first study dose; or use of an invasive investigational medical device;
  • Administration of an approved or emergency-use investigational vaccine (other than SARS-CoV-2 vaccines) within 4 weeks; administration of live attenuated vaccines within 4 weeks;
  • Monoclonal antibody therapy within 21 days;
  • Cytotoxic chemotherapy within 21 days;
  • Proteasome inhibitor (PI) therapy within 14 days;
  • Immunomodulatory drug (IMiD) therapy within 14 days;
  • Radiotherapy within 14 days, or focal palliative radiotherapy within 7 days.
  • 3. CNS Involvement: Known active central nervous system (CNS) involvement or clinical signs of meningeal myeloma. In suspected cases, brain MRI and lumbar puncture cytology must be negative.
  • 4. Specific Hematologic Conditions: Diagnosis of plasma cell leukemia, Waldenstrom macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes), or primary light chain (AL) amyloidosis at screening.
  • 5. Second Malignancies: Non-hematologic malignancy diagnosed within 3 years prior to enrollment (unless curatively treated), or presence of therapy-related myelodysplastic syndrome (t-MDS).
  • 6. Cardiovascular Diseases: Cardiovascular diseases including:
  • New York Heart Association (NYHA) Class III or IV congestive heart failure;
  • Myocardial infarction or coronary artery bypass grafting (CABG) within 6 months prior to enrollment;
  • Clinically significant ventricular arrhythmias, or history of unexplained syncope;
  • History of severe non-ischemic cardiomyopathy.
  • 7. Infectious & Pulmonary Diseases: Infectious, pulmonary, or neurologic conditions including:
  • Uncontrolled hepatitis B virus infection (positive HBsAg or HBV-DNA): if infection status is indeterminate, HBV-DNA viral quantification must be performed. Active hepatitis C virus (HCV) infection, defined as positive HCV-RNA. Patients with a history of HCV antibody positivity must undergo HCV-RNA testing; patients with resolved chronic hepatitis C who completed antiviral therapy and maintained undetectable HCV-RNA for >= 12 weeks post-treatment are eligible;
  • Chronic obstructive pulmonary disease (COPD) with FEV1 < 50% of predicted normal value;
  • Moderate or severe persistent asthma within the past 2 years, or uncontrolled asthma of any type;
  • Significant peripheral neuropathy at baseline (Grade 3, Grade 4, or Grade 2 with associated pain).
  • 8. Major Surgery: Major surgery within 2 weeks prior to initiating study treatment, incomplete surgical recovery, or major elective surgery planned during the study treatment period or within 2 weeks following the last study dose.
  • 9. Investigator Discretion: Any medical, psychiatric, or other condition that, in the opinion of the investigator, makes the patient unsuitable for trial participation.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:SKCD:Sonrotoclax+Carfilzomib+Aponermin+Dexamethasone

Eligible patients will receive the SKCD regimen for up to 9 cycles (28 days per cycle). Patients who do not develop disease progression or meet withdrawal criteria proceed to Kd maintenance therapy:

  • Cycle 1 (C1, 28-day cycle): Sonrotoclax: Oral dose ramp-up / escalated to 320 mg QD, PO, Days 1-28; Carfilzomib: 20 mg/m² IV on Days 1 and 2, then 27 mg/m² IV on Days 8, 9, 15, and 16; Aponermin (CPT): 10 mg/kg IV on Days 1-5; Dexamethasone: 20 mg PO or IV on Days 1, 2, 8, 9, 15, 16, 22, and 23.
  • Cycles 2 to 9 (C2-C9, 28-day cycles): Sonrotoclax: 320 mg QD, PO, Days 1-28; Carfilzomib: 27 mg/m² IV on Days 1, 2, 8, 9, 15, and 16; Aponermin (CPT): 10 mg/kg IV on Days 1-5; Dexamethasone: 20 mg PO or IV on Days 1, 2, 8, 9, 15, 16, 22, and 23.
  • Post-Cycle 9 Kd Maintenance Phase (28-day cycles): Carfilzomib: 27 mg/m² IV on Days 1, 2, 15, and 16; Dexamethasone: 10 mg PO or IV on Days 1, 2, 15, and 16.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Best Complete Response or Better Rate (≥CR)
時間枠:From enrollment to the end of treatment at 9 cycles (28 days per cycle)

The proportion of participants who achieve a confirmed complete response (CR) or stringent complete response (sCR), according to the International Myeloma Working Group criteria, during the first nine cycles of SKCD treatment and before initiation of Kd maintenance therapy.

From enrollment to the end of treatment at 9 cycles (28 days per cycle)

二次結果の測定

結果測定
メジャーの説明
時間枠
Best Complete Response or Better Rate During SKCD and Kd Maintenance
時間枠:From enrollment to the end of treatment at 9 cycles (28 days per cycle)].

The proportion of participants whose best confirmed response is complete response (CR) or stringent complete response (sCR), assessed according to the International Myeloma Working Group criteria from the first dose of study treatment through SKCD treatment and subsequent Kd maintenance, before disease progression or initiation of a new anti-myeloma treatment, whichever occurs first.

From enrollment to the end of treatment at 9 cycles (28 days per cycle)].
Overall Response Rate (ORR)
時間枠:From enrollment to the end of treatment at 9 cycles (28 days per cycle)

The proportion of participants who achieve a partial response (PR) or better as their best response, assessed according to the International Myeloma Working Group (IMWG) response criteria.

From enrollment to the end of treatment at 9 cycles (28 days per cycle)
Very Good Partial Response or Better Rate (≥VGPR)
時間枠:From enrollment to the end of treatment at 9 cycles (28 days per cycle)

The proportion of participants who achieve a very good partial response (VGPR), complete response (CR), or stringent complete response (sCR) as their best response, assessed according to the International Myeloma Working Group (IMWG) response criteria.

From enrollment to the end of treatment at 9 cycles (28 days per cycle)
Minimal Residual Disease (MRD) Negativity Rate by Next-Generation Flow Cytometry
時間枠:From enrollment to the end of treatment at 9 cycles (28 days per cycle), during maintenance treatment

The proportion of participants who achieve minimal residual disease (MRD) negativity in bone marrow, assessed by next-generation flow cytometry (NGF) at a sensitivity of 10^-5. Bone marrow MRD is assessed when a participant achieves a very good partial response (VGPR) or better. The proportion of participants who achieve MRD negativity among participants who undergo bone marrow MRD testing by next-generation flow cytometry at a sensitivity of 10^-5.

From enrollment to the end of treatment at 9 cycles (28 days per cycle), during maintenance treatment
Progression-Free Survival (PFS)
時間枠:From the first dose of study treatment until disease progression or death from any cause, assessed up to 36 months.

The time from the first dose of study treatment to the first documented disease progression, assessed according to the International Myeloma Working Group (IMWG) response criteria, or death from any cause, whichever occurs first.

From the first dose of study treatment until disease progression or death from any cause, assessed up to 36 months.
Overall Survival (OS)
時間枠:From the first dose of study treatment until death for any cause, assessed up to 36 months.

The time from the first dose of study treatment to death from any cause.

From the first dose of study treatment until death for any cause, assessed up to 36 months.
Incidence and Severity of Adverse Events
時間枠:From signing of informed consent through the post-treatment safety visit 60 days after the final dose of study treatment.

Number and proportion of participants experiencing adverse events, serious adverse events, and adverse events leading to dose modification or treatment discontinuation. Adverse events will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 6.0.

From signing of informed consent through the post-treatment safety visit 60 days after the final dose of study treatment.

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Wen Gao, MD、Beijing Chao Yang Hospital

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

一般刊行物

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年10月31日

一次修了 (推定)

2030年3月31日

研究の完了 (推定)

2030年3月31日

試験登録日

最初に提出

2026年10月29日

QC基準を満たした最初の提出物

2026年11月6日

最初の投稿 (実際)

2026年11月12日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月12日

QC基準を満たした最後の更新が送信されました

2026年11月6日

最終確認日

2026年10月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

IPD プランの説明

Individual participant data (IPD) will not be made publicly available due to participant privacy and confidentiality considerations. Aggregate study results may be reported in scientific publications.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

米国で製造され、米国から輸出された製品。

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する